
Programs: Science and Policy
http://shr.aaas.org//projects/personalized_med/index.shtml
AAAS Scientific Responsibility, Human Rights and Law Program
Scientific advances in such fields as genomics, proteomics, and imaging hold the promise of leading to an era of personalized medicine, where diagnoses will be more precise and treatments more targeted. Personalized medicine can also increases patient safety, as patient profiles indicate which drugs are suited for which people, at what dose, and which patients might suffer from adverse drug reactions.
Many challenges remain before the promises of personalized medicine are realized. The pharmaceutical industry will have to shift from a business model that emphasizes blockbuster drugs to one producing many specialized medications for subgroups of patients. Regulatory agencies will have to determine if existing policies are adequate. For example, the FDA will have to craft methods for evaluating diagnostics and companion drugs simultaneously. Health care providers will need to consider how best to apply the new science to their patients. A system of secure electronic health records for individual patients must be developed. Parallel with these changes, social, ethical, and legal issues must be openly discussed.
|
 |
| |
 |
 |
 |
 |
Colloquia Series on Personalized Medicine
[2009-2010]
The colloquia addressed the scientific discoveries, business models, and regulatory changes that are necessary to develop new personalized treatments and their companion diagnostics. Other sessions focused on electronic health records, reimbursement, education of patients and their care givers, and such ethical, legal, and policy issues as privacy, patients’ responsibility for their own health, and direct to consumer testing, among others. More... |
 |
 |
|
 |
|
|
 |
| |
 |
| |
|
(page updated
11/30/2012)
|